Fecal calprotectin testing for inflammatory bowel disease in patients presenting with lower gastrointestinal symptoms: a retrospective primary care cohort study in the United Kingdom.

Authors

Nosheen Umar, Steven Wambua, Phil Harvey, Nicola J Adderley, Shamil Haroon, Nigel Trudgill

Published in

Inflammatory bowel diseases. Oct 29, 2026. Epub Oct 29, 2026.

Abstract

Fecal calprotectin (FC) can help to differentiate inflammatory bowel disease (IBD) from other causes of lower gastrointestinal (GI) symptoms. This study aimed to study FC testing in primary care, associated factors, subsequent secondary care referrals and IBD diagnoses.
A retrospective cohort study was conducted using primary care data in England. Adults aged 18-60 with lower GI symptoms between 2015 and 2023 were included. FC testing 30 days before to 3 months after a recorded lower GI symptom was examined. A random-effects logistic regression model explored patient-level factors associated with FC testing. Referral pathways and diagnostic outcomes among patients with FC testing were examined.
Of 830 936 symptomatic patients, 34 944 (4.2%) had FC testing. FC testing increased from 1.6% of symptomatic patients in 2015 to 7.7% in 2023 (P = .001). Factors negatively associated with FC testing included female sex (adjusted odds ratio [aOR], 0.80; 95% CI, 0.78-0.82), lower socioeconomic status (aOR, 0.90; 95% CI, 0.86-0.95), smoking (aOR, 0.86; 95% CI,, 0.83-0.89) and obesity (aOR, 0.92; 95% CI, 0.89-0.95). Among patients referred to gastroenterology, 23.7% with FC >250µg/g were diagnosed with IBD, but only 4.1% with FC 100-250µg/g. Among patients with rectal bleeding and FC 100-250µg/g, 9% had IBD. Despite normal FC results (<100µg/g), 25.2% of symptomatic patients were still referred to secondary care, of whom 0.5% were diagnosed with IBD and 1% with colorectal cancer.
FC can effectively triage primary care patients with suspected IBD. Despite negative FC results, a significant proportion of patients were still referred to secondary care, with very few diagnosed with IBD.

PMID:
42955803
Bibliographic data and abstract were imported from PubMed on 30 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.